138 related articles for article (PubMed ID: 24603590)
61. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
62. Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients.
Wang J; Zhou M; Zhang QG; Xu J; Lin T; Zhou RF; Li J; Yang YG; Chen B; Ouyang J
Oncotarget; 2017 Feb; 8(6):9708-9716. PubMed ID: 28039454
[TBL] [Abstract][Full Text] [Related]
63. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
64. [Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].
Chen Y; Chen H; Fu K; Zhu XZ; Irons R
Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):313-8. PubMed ID: 20654154
[TBL] [Abstract][Full Text] [Related]
65. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
Cai Q; Tu M; Xu-Monette ZY; Sun R; Manyam GC; Xu X; Tzankov A; Hsi ED; Møller MB; Medeiros LJ; Ok CY; Young KH
Mod Pathol; 2017 Jun; 30(6):854-876. PubMed ID: 28281555
[TBL] [Abstract][Full Text] [Related]
66. The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas.
Rayman N; Lam KH; van der Holt B; Koss C; van Leeuwen J; Budel LM; Mulder AH; Sonneveld P; Delwel R
Eur J Haematol; 2011 Jun; 86(6):466-76. PubMed ID: 21457344
[TBL] [Abstract][Full Text] [Related]
67. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China].
Chen Y; Xiao L; Zhu X; Lu C; Yu B; Fan D; Yin Y
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):383-8. PubMed ID: 25208988
[TBL] [Abstract][Full Text] [Related]
68. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
[TBL] [Abstract][Full Text] [Related]
69. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
70. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
[TBL] [Abstract][Full Text] [Related]
71. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
72. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
Rodig SJ; Savage KJ; LaCasce AS; Weng AP; Harris NL; Shipp MA; Hsi ED; Gascoyne RD; Kutok JL
Am J Surg Pathol; 2007 Jan; 31(1):106-12. PubMed ID: 17197926
[TBL] [Abstract][Full Text] [Related]
73. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.
Ruminy P; Etancelin P; Couronné L; Parmentier F; Rainville V; Mareschal S; Bohers E; Burgot C; Cornic M; Bertrand P; Lenormand B; Picquenot JM; Jardin F; Tilly H; Bastard C
Leukemia; 2011 Apr; 25(4):681-8. PubMed ID: 21233831
[TBL] [Abstract][Full Text] [Related]
74. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment.
Xia ZG; Xu ZZ; Zhao WL; Zhao SQ; Ding F; Chen Y; Chen QS; Zheng Y; Zhu Q; Hu JP; Shen ZX; Li JM
Ann Hematol; 2010 Feb; 89(2):171-7. PubMed ID: 19669764
[TBL] [Abstract][Full Text] [Related]
75. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
76. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
77. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
78. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
79. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
Zhao S; Dong X; Shen W; Ye Z; Xiang R
Cancer Med; 2016 May; 5(5):837-52. PubMed ID: 26869285
[TBL] [Abstract][Full Text] [Related]
80. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
Hwang HS; Yoon DH; Hong JY; Park CS; Lee YS; Ko YH; Kim SJ; Kim WS; Suh C; Huh J
Ann Hematol; 2018 Dec; 97(12):2363-2372. PubMed ID: 30069703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]